OverviewSuggest Edit

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.
TypePublic
Founded1997
HQAmsterdam, NL
Websitekiadis.com

Latest Updates

Employees (est.) (Aug 2020)5(-81%)
Share Price (Sept 2020)€1.6 (+4%)
Cybersecurity ratingBMore

Key People/Management at Kiadis Pharma

Arthur Lahr

Arthur Lahr

Chief Executive Officer
Berndt Modig

Berndt Modig

Board Member
Mark Wegter

Mark Wegter

Chairman of the Supervisory Board
Amy Sullivan

Amy Sullivan

Chief Strategy Officer
Otto Schwarz

Otto Schwarz

Board Member
Robert Friesen

Robert Friesen

Chief Scientific Officer
Show more

Kiadis Pharma Office Locations

Kiadis Pharma has an office in Amsterdam
Amsterdam, NL (HQ)
Paasheuvelweg 25a
Show all (1)

Kiadis Pharma Financials and Metrics

Kiadis Pharma Revenue

Market capitalization (23-Sept-2020)

48.5m

Closing stock price (23-Sept-2020)

1.6
Kiadis Pharma's current market capitalization is €48.5 m.
Show all financial metrics

Kiadis Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Kiadis Pharma Online and Social Media Presence

Embed Graph

Kiadis Pharma News and Updates

Kiadis Pharma announces abstract accepted for presentation at the 2020 ISCT Annual Meeting

Amsterdam, The Netherlands, May 25, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces an abstract highlighting data related to the Company’s natural killer (NK) cell therapy program has bee…

Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21

                                               Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21

Kiadis Pharma to present at BioCapital Europe 2020

Amsterdam, The Netherlands, March 4, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that Arthur Lahr, chief executive officer, will present at BioCapital Europe 2020 in Amsterdam on Thur…

Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors

Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, and The Ohio State University - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (“OSU” or “OSUCC…

Kiadis Pharma announces formation of renowned Scientific Advisory Board

Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts in the field…
Show more

Kiadis Pharma Blogs

Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018

Amsterdam, The Netherlands, August 24, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse a…

Kiadis Pharma secures €20 million debt financing facility from Kreos Capital

Amsterdam, The Netherlands, August 1, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse af…
Show more

Kiadis Pharma Frequently Asked Questions

  • When was Kiadis Pharma founded?

    Kiadis Pharma was founded in 1997.

  • Who are Kiadis Pharma key executives?

    Kiadis Pharma's key executives are Arthur Lahr, Berndt Modig and Mark Wegter.

  • How many employees does Kiadis Pharma have?

    Kiadis Pharma has 5 employees.

  • Who are Kiadis Pharma competitors?

    Competitors of Kiadis Pharma include LGC, Keryx Biopharmaceuticals and NovaBay Pharmaceuticals.

  • Where is Kiadis Pharma headquarters?

    Kiadis Pharma headquarters is located at Paasheuvelweg 25a, Amsterdam.

  • Where are Kiadis Pharma offices?

    Kiadis Pharma has an office in Amsterdam.

  • How many offices does Kiadis Pharma have?

    Kiadis Pharma has 1 office.